Regarding CIT-BCL2i associations, the phase 1b CAVALLI trial (45) evaluated venetoclax combined with R-CHOP or G-CHOP in frontline or R/R NHL (43% FL). The gene discussed is DDIT3; the disease is non-Hodgkin lymphoma.